Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 131830, 4 pages
Research Article

Qiliqiangxin Affects L Type Current in the Normal and Hypertrophied Rat Heart

1Department of Cardiology, Shanghai Tenth People’s Hospital of Tongji University, 301 Yanchang Road, Shanghai 200072, China
2Department of Traditional Chinese Medicine, Shanghai Tenth People’s Hospital of Tongji University, 301 Yanchang Road, Shanghai 200072, China

Received 24 November 2011; Accepted 19 January 2012

Academic Editor: Hao Xu

Copyright © 2012 Yidong Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Qiliqiangxin capsule is newly developed Chinese patent drug and proved to be effective and safe for the treatment of patients with chronic heart failure. We compared the effects of different dose Qiliqiangxin on L type Ca2+ current between normal and hypertrophied myocytes. A total of 40 healthy Sprague—Dawley rats were used in the study. The rats were randomly divided into two groups (control group and hypertrophy group). Cardiac hypertrophy was induced by pressure overload produced by partial ligation of the abdominal aorta. The control group was the sham-operated group. After 1 month, cardiac ventricular myocytes were isolated from the hearts of rats. Ventricular myocytes were exposed to 10 and 50 μmol/L Qiliqiangxin, and whole cell patch-clamp technique was used to study the effects of Qiliqiangxin on . The current densities of were similar in control group and in hypertrophy group . They were not statistically significant. 10 and 50 μmol/L Qiliqiangxin can decrease peak current and in control group. However, the peak current was only reduced by 50 μmol/L Qiliqiangxin in hypertrophied myocytes. The inhibited action of Qiliqiangxin on of hypertrophy group was lower than in control group. Qiliqiangxin affected L-type Ca2+ channel and blocked , as well as affected cardiac function finally. Qiliqiangxin has diphasic action that is either class IV antiarrhythmic agent or the agent of effect cardiac function.